Institut Català de la Salut
[Rocca MA, Preziosa P] Neuroimaging Research Unit, Division of Neuroscience, IRCCS San Raffaele Scientific Institute, Milan, Italy. Neurology Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy. Vita-Salute San Raffaele University, Milan, Italy. [Barkhof F] Department of Radiology & Nuclear Medicine, Amsterdam UMC, Vrije Universiteit, Amsterdam, the Netherlands. Queen Square Institute of Neurology and Centre for Medical Image Computing, University College London, London, UK. [Brownlee W] Queen Square MS Centre, Department of Neuroinflammation, UCL Institute of Neurology, London, UK. [Calabrese M] The Multiple Sclerosis Center of University Hospital of Verona, Department of Neurosciences and Biomedicine and Movement, Verona, Italy. [De Stefano N] Department of Medicine, Surgery and Neuroscience, University of Siena, Siena, Italy. [Vidal-Jordana À] Servei de Neurologia-Neuroimmunologia, Centro de Esclerosis Múltiple de Catalunya (CEMCAT), Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain
Vall d'Hebron Barcelona Hospital Campus
2025-02-18T11:34:16Z
2025-02-18T11:34:16Z
2024-09
Diagnosis; Magnetic resonance imaging; Multiple sclerosis
Diagnòstic; Imatge per ressonància magnètica; Esclerosi múltiple
Diagnóstico; Imagen por resonancia magnética; Esclerosis múltiple
In the majority of cases, multiple sclerosis (MS) is characterized by reversible episodes of neurological dysfunction, often followed by irreversible clinical disability. Accurate diagnostic criteria and prognostic markers are critical to enable early diagnosis and correctly identify patients with MS at increased risk of disease progression. The 2017 McDonald diagnostic criteria, which include magnetic resonance imaging (MRI) as a fundamental paraclinical tool, show high sensitivity and accuracy for the diagnosis of MS allowing early diagnosis and treatment. However, their inappropriate application, especially in the context of atypical clinical presentations, may increase the risk of misdiagnosis. To further improve the diagnostic process, novel imaging markers are emerging, but rigorous validation and standardization is still needed before they can be incorporated into clinical practice. This Series article discusses the current role of MRI in the diagnosis and prognosis of MS, while examining promising MRI markers, which could serve as reliable predictors of subsequent disease progression, helping to optimize the management of individual patients with MS. We also explore the potential of new technologies, such as artificial intelligence and automated quantification tools, to support clinicians in the management of patients. Yet, to ensure consistency and improvement in the use of MRI in MS diagnosis and patient follow-up, it is essential that standardized brain and spinal cord MRI protocols are applied, and that interpretation of results is performed by qualified (neuro)radiologists in all countries.
Article
Versió publicada
Anglès
Esclerosi múltiple - Imatgeria per ressonància magnètica; Esclerosi múltiple - Prognosi; DISEASES::Nervous System Diseases::Autoimmune Diseases of the Nervous System::Demyelinating Autoimmune Diseases, CNS::Multiple Sclerosis; Other subheadings::Other subheadings::Other subheadings::/diagnostic imaging; ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Diagnosis::Prognosis; ENFERMEDADES::enfermedades del sistema nervioso::enfermedades autoinmunitarias del sistema nervioso::enfermedades autoinmunes desmielinizantes del SNC::esclerosis múltiple; Otros calificadores::Otros calificadores::Otros calificadores::/diagnóstico por imagen; TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::diagnóstico::pronóstico
Elsevier
The Lancet Regional Health - Europe;44
https://doi.org/10.1016/j.lanepe.2024.100978
Attribution 4.0 International
http://creativecommons.org/licenses/by/4.0/